Fluvoxamine, Anti-Depressant Drug That Becomes a Candidate for COVID-19 Drugs

A number of drugs have been tested for the treatment of COVID-19. Newest, antidepressant Fluvoxamine has shown promise for preventing treatment risks in COVID-19 patients.

Fluvoxamine is usually prescribed for obsessive-compulsive disorder or OCD (obsessive-compulsive disorder). This drug works by increasing the hormone serotonin in the brain’s nerve cells.

This idea started from a study in Brazil in June 2020. Quoted from Lancet Global Health (27/10/2021), observations have been continued at the stage of randomized controlled clinical trials on a larger scale.

After screening 9,803 participants, this study was finally carried out with 741 patients receiving Fluvoxamine and 756 others received a placebo.

The results showed that the use of Fluvoxamine caused 11 percent (79 patients) to require hospitalization, while in placebo about 16 percent were hospitalized.

From the results of this study, it is known that the use of Fluvoxamine (100 mg 2 times a day for 10 days) for patients can reduce the need for hospital care. Because it has been used for a long time clinically, Fluvoxamine, could be a new candidate for the treatment of COVID-19.

“This drug (Fluvoxamine) has been used clinically for 2-3 decades, has been consumed by millions of people, and can be found in almost any pharmacy in America for $10,” said David Boulware, an infectious disease physician and researcher at the University of Minnesota. Science News.

Watch Videos”Even though the case is sloping, the Covid-19 task force warns that the pandemic is not over“
[Gambas:Video 20detik]
(naf/up)

– .